cutting-edge AI technologies
To be a global leader integrating biopharma and AI
To build a healthier world and to make innovative medicines accessible
Galixir is dedicated to bringing more value into the medical industry with diversifying pipelines, especially on undruggable and difficult-to-drug targets.
Integrating tools and experience of computational chemistry, medicinal chemistry and biology, Pyxir®, the AI-driven drug discovery platform of Galixir, leverages cutting-edge AI algorithms to resolve problems in the preclinical development of small molecule drugs and to find candidate molecules with high potency, good druggability and novel structures. M1, the intelligent computing platform of Galixir combining AI with classical physics principles, makes breakthroughs in classical molecular modeling methods at the world’s top level. It is able to accurately describe the interactions between molecules and proteins, and predict the binding free energy between target drug molecules and specific targets with high efficiency and accuracy.
Galixir has identified a novel preclinical compound candidate (PCC) for autoimmune diseases through Pyxir® and M1 platform, demonstrating its AI drug discovery capabilities in a closed loop. Galixir will continue to take “AI-driven drug discovery pipeline” and “AI-driven computing platform” as the dual cycle to empower drug discovery, in a bid to build a healthier world and to make new drugs accessible.
are from worldwide top-tier universities, first-rate Internet companies and renowned pharmaceutical enterprises
Galixir team members have rich experience in leading drug discovery projects to IND and FDA approval, and machine learning application experience in top-tier Internet companies including Google, Apple and Microsoft. Besides, Galixir has already published nearly 20 papers in top journals and conference proceedings, covering subjects including molecular generation, property prediction and virtual screening and so forth. And our models have kept the world performance record.
Galixir works together with domestic and oversea universities and research institutions including Georgia Institute of Technology, Massachusetts Institute of Technology, University of Pennsylvania, Google Brain of Google AI, Mila, Guangzhou Institutes of Biomedicine and Health of Chinese Academy of Science, Institute of Microbiology of Chinese Academy of Science, Shanghai Jiao Tong University, Zhejiang University and Sun Yat-sen University.